Cargando…
Benefit and danger from immunotherapy in myasthenia gravis
In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement i...
Autores principales: | Rodolico, Carmelo, Nicocia, Giulia, Damato, Valentina, Antonini, Giovanni, Liguori, Rocco, Evoli, Amelia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861968/ https://www.ncbi.nlm.nih.gov/pubmed/33543421 http://dx.doi.org/10.1007/s10072-021-05077-6 |
Ejemplares similares
-
Controversies in Ocular Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2020) -
Editorial: News and Views in the Management of Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2021) -
Human Leukocyte Antigen Class II associations in late‐onset Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2021) -
Novel Immunotherapies for Myasthenia Gravis
por: Nair, Sruthi S, et al.
Publicado: (2023) -
Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience
por: Farina, Antonio, et al.
Publicado: (2022)